Scancell Holdings Regulatory News (SCLP)

Hardman Research - Validating multiple opportunities

Validating and de-risking of multiple opportunities: Scancell is a clinical-stage biotechnology company developing two distinct flexible cancer immunotherapy platforms, each with broad applications: ImmunoBody is a DNA vaccine that stimulates high-avidity anti-tumour CD8+ T-cells for use as a monotherapy or in combination with checkpoint inhibitors (CPIs); Moditope targets modified antigens and stimulates powerful anti-tumour CD4+ T-cell responses for use in advanced and hard-to-treat cancers. Both technologies have been externally validated recently through partnership deals with Cancer Research UK (CRUK; ImmunoBody SCIB2) and BioNTech (Moditope), providing significant endorsements.

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/scancell-documents/15.02.18-validating-and-de-risking-of-multiple-opportunities.pdf

About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.